Strategic Acquisition The recent acquisition of CHEORS by PharmAlliance presents opportunities to leverage expanded resources and client networks, facilitating cross-selling of advanced HEOR and market access services to a broader pharmaceutical and biotech customer base.

Market Expansion CHEORS’ focus on health economic insights, economic modeling, and HTA submissions positions it well to support pharmaceutical companies seeking to accelerate product approvals and reimbursement through enhanced value demonstration.

Technological Integration Using diverse digital tools such as WordPress, MySQL, and animation libraries demonstrates CHEORS’s capability to implement innovative, tech-driven solutions that can be marketed to clients seeking cutting-edge health economic analytics.

Industry Focus Operating within the pharmaceutical manufacturing sector, CHEORS offers tailored HEOR services that target companies preparing for market entry and reimbursement, creating potential upsell opportunities for comprehensive consulting packages.

Growth Potential With a revenue estimate of $10M to $25M and a skilled team of up to 200 employees, CHEORS is positioned for scalable growth, making it a prime prospect for strategic partnerships or enterprise service expansion initiatives.